Autopsy report · NCT00991887

Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma

“there was an unacceptably high adverse event rate in the treatment group.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 years 1 month after it had already started.
• Ran for about 4 years 10 months before it stopped.
• 48 participants enrolled.
• Results were posted on the registry 7 years 2 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Wake Forest University Health Sciences

Sponsor type

University, hospital or other

Conditions

Elbow Fracture

Interventions

Radiation Therapy (XRT)

Participants

48

Trials that died the same way

• Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)
  “investigation of adverse events in a related clinical study” (67% match in meaning)
• Ipilimumab + Androgen Depravation Therapy in Prostate Cancer
  “Due to adverse events” (66% match in meaning)
• Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
  “Adverse Events” (65% match in meaning)
• Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery
  “Adverse Event” (65% match in meaning)
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
  “Other - Adverse Events” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.